UTAH MEDICAL PRODUCTS, INC. (UTMD) Operating Margin
- Operating margin · 12 months: Value 28.44%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 28.44% | Operating income / revenue. Period ending 2026-06-30. $10.27M ÷ $36.11M × 100 ≈ 28.44% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 10.27M USD | Operating Income (Loss) |
| Revenue | 36.11M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 15.20M USD | Cost of Goods and Services Sold |
| Research and development | 687.00K USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.27M | $36.11M | $15.20M | $687.00K | (m) | 28.44% |
| 2026-03-31 | $10.81M | $37.53M | $15.79M | $668.00K | (m) | 28.81% |
| 2025-12-31 | $11.40M | $38.52M | $16.52M | $668.00K | (m) | 29.60% |
| 2025-09-30 | $11.89M | $38.63M | $16.57M | $577.00K | (m) | 30.78% |
| 2025-06-30 | $12.62M | $38.83M | $16.57M | $581.00K | (m) | 32.51% |
| 2025-03-31 | $12.86M | $39.27M | $16.36M | $701.00K | (m) | 32.76% |
| 2024-12-31 | $13.59M | $40.90M | $16.76M | $813.00K | (m) | 33.23% |
| 2024-09-30 | $14.61M | $44.08M | $18.16M | $838.00K | (m) | 33.14% |
| 2024-06-30 | $15.23M | $46.58M | $19.10M | $804.00K | (m) | 32.71% |
| 2024-03-31 | $16.22M | $49.04M | $20.08M | $682.00K | (m) | 33.07% |
| 2023-12-31 | $16.78M | $50.22M | $20.19M | $560.00K | (m) | 33.40% |
| 2023-09-30 | $17.90M | $51.47M | $20.20M | $537.00K | (m) | 34.79% |
| 2023-06-30 | $19.07M | $51.91M | $19.82M | $512.00K | (m) | 36.74% |
| 2023-03-31 | $19.71M | $52.48M | $19.97M | $514.00K | (m) | 37.55% |
| 2022-12-31 | $19.79M | $52.28M | $20.09M | $493.00K | (m) | 37.85% |
| 2022-09-30 | $19.85M | $51.62M | $19.64M | $511.00K | (m) | 38.45% |
| 2022-06-30 | $19.81M | $51.24M | $19.37M | $525.00K | (m) | 38.66% |
| 2022-03-31 | $19.51M | $50.41M | $18.91M | $519.00K | (m) | 38.71% |
| 2021-12-31 | $18.88M | $49.05M | $18.14M | $526.00K | (m) | 38.49% |
| 2021-09-30 | $18.03M | $48.15M | $18.08M | $496.00K | (m) | 37.45% |
| 2021-06-30 | $16.52M | $46.06M | $17.56M | $495.00K | (m) | 35.87% |
| 2021-03-31 | $13.73M | $42.24M | $16.58M | $481.00K | (m) | 32.51% |
| 2020-12-31 | $13.71M | $42.18M | $16.63M | $486.00K | (m) | 32.50% |
| 2020-09-30 | $14.11M | $42.00M | $15.90M | $501.00K | (m) | 33.59% |
| 2020-06-30 | $14.89M | $44.01M | $17.04M | $505.00K | (m) | 33.83% |
| 2020-03-31 | $17.39M | $47.07M | $17.55M | $503.00K | (m) | 36.95% |
| 2019-12-31 | $17.63M | $46.90M | $17.44M | $483.00K | (m) | 37.59% |
| 2019-09-30 | $17.22M | $44.83M | $17.07M | $473.00K | (m) | 38.42% |
| 2019-06-30 | $17.25M | $42.73M | $16.05M | $452.00K | (m) | 40.38% |
| 2019-03-31 | $17.83M | $41.84M | $15.69M | $456.00K | (m) | 42.60% |
| 2018-12-31 | $18.70M | $42.00M | $15.69M | $454.00K | (m) | 44.52% |
| 2018-09-30 | $19.00M | $42.44M | (m) | $444.00K | (m) | 44.77% |
| 2018-06-30 | $19.28M | $42.18M | (m) | $439.00K | (m) | 45.71% |
| 2018-03-31 | $19.26M | $42.04M | (m) | $442.00K | (m) | 45.80% |
| 2017-12-31 | $19.01M | $41.41M | (m) | $447.00K | (m) | 45.90% |
| 2017-09-30 | $18.06M | $40.06M | (m) | $452.00K | (m) | 45.07% |
| 2017-06-30 | $17.32M | $39.59M | (m) | $484.00K | (m) | 43.74% |
| 2017-03-31 | $16.60M | $39.26M | (m) | $483.00K | (m) | 42.29% |
| 2016-12-31 | $16.19M | $39.30M | (m) | $475.00K | (m) | 41.19% |
| 2016-09-30 | $16.37M | $40.03M | (m) | $480.00K | (m) | 40.90% |
| 2016-06-30 | $16.43M | $40.32M | (m) | $455.00K | (m) | 40.76% |
| 2016-03-31 | $16.09M | $40.23M | (m) | $476.00K | (m) | 39.99% |
| 2015-12-31 | $15.65M | $40.16M | (m) | $522.00K | (m) | 38.97% |
| 2015-09-30 | $16.14M | $40.82M | (m) | $514.00K | (m) | 39.54% |
| 2015-06-30 | $16.14M | $41.59M | (m) | $518.00K | (m) | 38.81% |
| 2015-03-31 | $16.24M | $41.68M | (m) | $493.00K | (m) | 38.95% |
| 2014-12-31 | $16.20M | $41.28M | (m) | $460.00K | (m) | 39.25% |
| 2014-09-30 | $15.47M | $41.12M | (m) | $-508.00K | (m) | 37.61% |
| 2014-06-30 | $15.13M | $40.44M | (m) | $-496.00K | (m) | 37.41% |
| 2014-03-31 | $14.78M | $39.95M | (m) | $-491.00K | (m) | 37.00% |
| 2013-12-31 | $14.83M | $40.49M | (m) | $-491.00K | (m) | 36.62% |
| 2013-09-30 | $14.84M | $40.24M | (m) | $498.00K | (m) | 36.87% |
| 2013-06-30 | $15.13M | $40.70M | (m) | $513.00K | (m) | 37.19% |
| 2013-03-31 | $14.97M | $40.72M | (m) | $540.00K | (m) | 36.76% |
| 2012-12-31 | $15.20M | $41.55M | (m) | $563.00K | (m) | 36.57% |
| 2012-09-30 | $14.54M | $41.63M | (m) | $565.00K | (m) | 34.93% |
| 2012-06-30 | $14.12M | $41.92M | (m) | $563.00K | (m) | 33.68% |
| 2012-03-31 | $13.80M | $42.27M | (m) | $563.00K | (m) | 32.64% |
| 2011-12-31 | $11.84M | $37.86M | (m) | $518.00K | (m) | 31.28% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $8.92M | $25.12M | (m) | $397.00K | (m) | 35.52% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $9.43M | $25.92M | (m) | $361.00K | (m) | 36.39% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |